ForPatients
by Roche

Healthy Volunteers

A study to find out if taking different forms of GDC-0134 gives you the same amount of medicine in your body

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03807739 GP40957

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a two-part study to determine the relative bioavailability of two different prototype capsules of GDC-0134 to that of an existing reference capsule of GDC-0134 under both fed and fasted conditions. The study is open to healthy female participants of non-childbearing potential.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03807739 GP40957
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>=18 Years & <= 65 Years	Accepts Healthy Volunteers

This clinical trial was done to study a new medicine called, “GDC-0134”, for the treatment of patients with “amyotrophic lateral sclerosis” – also known as “ALS” and “Lou Gehrig’s disease”. This study was done to find out whether taking three different forms (different formulations) of GDC-0134 gave you the same amount of medicine in your body. The effect of taking the medicine with and without food was also studied. The impact of the medicine on patients with ALS was not studied. Twenty-nine healthy people participated in this study at two study centers in USA.

© 2022 F. Hoffmann-La Roche Ltd